Literature DB >> 57226

Quantitative electromyography in the detection of the carriers in Duchenne type muscular dystrophy.

G Valli, G Scarlato, M Contartese.   

Abstract

The quantitative EMG technique was used to detect Duchenne muscular dystrophy carriers. The tests were carried out, measuring the parameters of M.U. potentials (the duration, the phase, and the 0 index according to Van den Bosch, modified by Gardner-Medwin), and using the Willison analyzer, in a group of carriers and normal subjects. Ten M.U. potentials from the deltoid, biceps brachii and quadriceps muscles were photographed and measured in each subject, and the right and the left biceps were examined with the Willison analyzer. An high detection rate was obtained by manual EMG, measuring traditional values such as mean number of phases, A.P. duration and 0 index. The Willison analyzer was significant in 2 known carriers. The total EMG detection rate was higher than the CPK tests both in the known carriers and the possible carriers. It is concluded that the quantitative EMG technique is an useful and specific test to detect carriers of the gene of Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 57226     DOI: 10.1007/bf00329157

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  SERUM ENZYME STUDIES IN MUSCLE DISEASE. III. SERUM CREATINE KINASE ACTIVITY IN RELATIVES OF PATIENTS WITH THE DUCHENNE TYPE OF MUSCULAR DYSTROPHY.

Authors:  J M PEARCE; R J PENNINGTON; J N WALTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1964-06       Impact factor: 10.154

2.  CREATINE KINASE LEVELS IN WOMEN WHO CARRY GENES FOR THREE TYPES OF MUSCULAR DYSTROPHY.

Authors:  K M WILSON; K A EVANS; C O CARTER
Journal:  Br Med J       Date:  1965-03-20

3.  Action potential parameters in different human muscles.

Authors:  F BUCHTHAL; P ROSENFALCK
Journal:  Acta Psychiatr Neurol Scand       Date:  1955

4.  [Serum creatine phosphokinase in various muscular diseases seen in the field of orthopedic surgery].

Authors:  A Iwamoto
Journal:  Igaku Kenkyu       Date:  1969-05

5.  Studies of the carrier state in the Duchenne type of muscular dystrophy. 2. Quantitative electromyography as a method of carrier detection.

Authors:  D Gardner-Medwin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1968-04       Impact factor: 10.154

6.  Carrier detection in Duchenne muscular dystrophy. A comparative study of electron microscopy, light microscopy and serum enzymes.

Authors:  S Roy; V Dubowitz
Journal:  J Neurol Sci       Date:  1970-07       Impact factor: 3.181

7.  The detection of carriers of X-linked muscular dystrophy genes. A review of some methods studied in Newcastle upon Tyne.

Authors:  D Gardner-Medwin; R J Pennington; J N Walton
Journal:  J Neurol Sci       Date:  1971-08       Impact factor: 3.181

8.  Creatine phosphokinase in neuromuscular disease. Patients and families.

Authors:  I Goto; H A Peters; H H Reese
Journal:  Arch Neurol       Date:  1967-05

9.  Quantitative electromyography using automatic analysis: studies in healthy subjects and patients with primary muscle disease.

Authors:  A L Rose; R G Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1967-10       Impact factor: 10.154

10.  Quantitative electromyography: carrier detection in Duchenne type muscular dystrophy using a new automatic technique.

Authors:  A Moosa; B H Brown; V Dubowitz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-12       Impact factor: 10.154

  10 in total
  3 in total

Review 1.  Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention.

Authors:  H Moser
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

2.  The female carrier of Duchenne muscular dystrophy.

Authors:  V Dubowitz
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-15

3.  Quantitative EMG and histological carrier detection of Duchenne muscular dystrophy.

Authors:  G Scarlato; G Valli; G Meola; L Carenini
Journal:  J Neurol       Date:  1977-11-01       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.